Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,735.45
(
0.54%
)
US TECH 100
24,191.60
(
0.73%
)
Dow Jones
47,161.93
(
0.46%
)
Brent Oil
100.18
(
1.91%
)
Bitcoin
73,776.01
(
-1.43%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 65635

Wednesday, 08/27/2008 9:57:54 AM

Wednesday, August 27, 2008 9:57:54 AM

Post# of 257251
Re: Apixaban dose

>These safety vs. efficacy results make me wonder if Apixaban's dose wasn't too low.<

You could be right. The Apixaban doses being tested in phase-3 for VTE treatment (as opposed to VTE prevention) are higher than the 2.5mg BID dose in the failed ADVANCE-1 trial. For instance, the AMPLIFY trial uses a loading dose of 10mg BID followed by a maintenance dose of 5mg BID (#msg-29928836).

Moreover, the phase-2 trial of Apixaban vs warfarin in VTE prevention employed doses of 5mg BID, 10mg BID, and 20mg qD (#msg-21044973).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now